Worth Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Worth Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$4.3K	–	487
2022 Q4	$4.3K	Hold	13	–	–	﹤0.01%	379
2022 Q3	$2K	Sell	13 -9	-41%	-$2.09K	﹤0.01%	402
2022 Q2	$5K	Hold	22	–	–	﹤0.01%	406
2022 Q1	$4K	Buy	+22	New	+$6.38K	﹤0.01%	424

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Worth Asset Management's BTAI Position: Q1 2023 in Review

Worth Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 13 shares — an estimated $4.3K sold.

Worth Asset Management first reported a position in BTAI in Q1 2022 and held it in 4 quarters. The position peaked at $5K in Q2 2022. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

Worth Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
Worth Asset Management sold 13 BioXcel Therapeutics shares in Q1 2023, an estimated $4.3K.
Worth Asset Management first reported a position in BioXcel Therapeutics in Q1 2022 and held it in 4 quarters.
Worth Asset Management's BioXcel Therapeutics position peaked at $5K in Q2 2022.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on Worth Asset Management's 13F filing for Q1 2023, filed 12 Apr 2023.